Globus Medical reported record revenue and strong financial performance, aiming for continued growth in 2025.
From Nasdaq: 2025-02-20 22:00:13
Globus Medical held its Q4 2024 earnings call on Feb 20, 2025. The company reported record revenue of $2.519 billion for the year, with a 61% growth from the previous year. Non-GAAP EPS was a record $3.04, and free cash flow reached an all-time high of $405 million. The company launched 18 new products in 2024 and achieved strong financial performance, paving the way for continued growth in 2025. In Q4, sales were $657 million, with non-GAAP EPS of $0.84 and free cash flow of $193 million. The company also launched five new products in the quarter, driving innovation in spine surgeries. Cortex MIS technology integrates with Excelsius for precise screw placement. Allegiance retractor offers quick setup and maximum rigidity. Radiolucent handheld blades ensure stable exposure. Modulus ALIF anchor and blades streamline surgical procedures. ExcelsiusFlex robotic navigation platform and ACTIFY unicondylar knee system launched in Q4. Exciting future launches planned for 2025. Enabling Technology sales for the quarter increased by 44%. Robotic procedures grew by 17%. DuraPro and Verzera Power Tool systems continue to stand out. Excelsius3D imaging system attracts high market interest. International spine implant business achieves record sales in Q4.
Integration with NuVasive product offering internationally shows strong potential. Definitive agreement to acquire Nevro Corporation for $250 million in all-cash transaction. Nevro’s high-frequency technology expands market reach. Acquisition seen as complementary to current spinal portfolio. Combination of sales forces to drive uptake and penetration. Financial strength of Globus to accelerate investments in neuromodulation. Acquisition expected to improve profitability and generate more cash for future growth opportunities. Exciting potential ahead for Globus. Globus Medical had a successful year in 2024, with revenue reaching $2.519 billion, an increase of 60.6% year-over-year. The company’s net income was $103 million, resulting in $0.75 of fully diluted earnings per share. Adjusted EBITDA was 29.2%, and they generated a record $405.2 million of free cash flow. In Q4 2024, revenue was $657.3 million, growing 6.6% year-over-year, with net income reaching $26.5 million. The U.S. and international spine businesses were primary growth drivers, with U.S. revenue growing 6.3% and international revenue growing 7.7%.
Globus Medical’s Q4 gross profit was 57.2%, an improvement from the previous year driven by operational improvements. Adjusted gross profit was 67.1%, driven by lower freight expenses and operational improvements. Full year 2024 GAAP gross profit was 55.6%, lower than the previous year due to inventory step-up amortization and higher product costs. Research and development expenses in Q4 were $33.4 million, reflecting cost savings and lower operational spending. For the full year, R&D expenses were $163.8 million, with increased dollar spending due to the inclusion of NuVasive for the full year. In the fourth quarter, SG&A expenses were $253.5 million or 38.6% of sales, decreasing from the previous year. Full-year 2024 SG&A expenses were $981 million, driven by higher sales and inclusion of NuVasive in consolidated figures. Operating and free cash flow reached record highs in Q4 and full year 2024. The company plans to pay off senior convertible notes in cash in March 2025. They also announced an agreement to acquire Nevro Corp for $250 million, expected to close in Q2 2025. Globus Medical reaffirms 2025 revenue guidance and earnings per share range. Globus Medical has entered the SCS market by acquiring Nevro. The decision was made due to the depth of integration from their previous acquisition of NuVasive in 2024. They see potential for growth beyond neuromodulation and plan to capitalize on high frequency technology. Despite competitor moves in the market, Globus remains focused on their long-term strategy of patient-centered innovation. The investment in Nevro will not significantly shift their investment focus, as they maintain a 6-7% range of investment. With strong robot placements in recent quarters, Globus is poised to penetrate the market further in 2025. In a recent conference call, NuVasive executives discussed their plans for the company in 2025, emphasizing a focus on in-sourcing manufacturing to improve gross margin. They anticipate a modest improvement in gross margin this year, with the most significant expansion expected in 2026. The company also plans to increase R&D investment in new product development to drive long-term growth.
Regarding the Nevro deal, NuVasive executives remained tight-lipped about future products and strategies, hinting at potential benefits for spinal implants. However, they emphasized a long-term approach to product development and stated that any new launches would be announced closer to the launch date. The deal is expected to drive profitability through sales growth and cost management, similar to their approach with the NuVasive merger. Nevro is seeing an increase in sales of imaging technology, both standalone and in packages, based on customer demand. Market challenges have slowed Nevro’s growth, but Globus believes their scale and balance sheet will drive success. M&A may be considered in the future, but organic growth opportunities are the focus. While the SI joint portfolio was not a key factor in acquiring Nevro, it could enhance Globus’ offerings. The launch of ExcelsiusFlex in Q4 is part of a long-term commercial strategy, with revenue impact expected to be minimal in 2025. Nevro’s CEO discusses the company’s plans to offer a variety of options for their new implants, focusing on a holistic approach to robotic procedures. Potential convergence between spine surgeons and interventionalists is considered, with a focus on high-frequency technology. The CEO remains cautiously optimistic about the spine market’s growth, expecting it to stay around 3% and focusing on outpacing it through innovation. Nevro plans to have a bigger presence at the upcoming AAOS conference and is prepared to support the growth of ambulatory surgery centers in the spine market. The company is also developing a navigation headset product with economic benefits. A new lightweight robotic surgical tool is in development, offering improved visualization and a direct line of sight for surgeons. With cameras that reduce interruptions and enhance teaching capabilities, the tool aims to revolutionize the operating room experience. The economic model for this tool will be complementary to existing capital, offering flexibility for customers. Sales projections for 2025 are estimated at $310 million to $340 million, with minimal tariff exposure expected due to U.S.-based sourcing. The goal is to achieve mid-30s EBITDA margins and drive operational improvements for long-term growth. Retention of sales reps post-merger remains a focus for the company. Pfeil, the COO and CFO of a company, discusses the strong capital market and customer purchasing trends. Majority of purchases are outright buys, but options for rental, leasing, and volume-based deals are available. Sales guidance for the year is optimistic, with a pending acquisition factored into the projections.
CEO Dan Scavilla highlights areas for potential growth in the spine business, including biologics and cross-selling opportunities with new assets. Focus on pediatric deformity and emerging technology are key areas of growth for the company in the coming year.
Globus Medical’s Chief Operating Officer and Chief Financial Officer, Keith Pfeil, discussed the company’s focus on gross margin expansion in year 3, as they bring machinery and products in-house. The company aims to see a working capital benefit in 2025 that will reflect on the P&L in 2026. Analysts raised questions about the impact of write-offs in inventory and bad debt expenses on the fourth-quarter results, which Keith Pfeil clarified. The company remains confident in achieving $170 million in synergies over three years, with a successful execution of year 1 and year 2. The call concluded with no further questions from participants. 1. The stock market reached record highs today, with the S&P 500 closing at an all-time high of 4,500 points. This surge was fueled by strong earnings reports from major tech companies like Apple and Amazon.
2. In global news, the United Nations reported that over 1 million people in Afghanistan are facing severe food shortages due to ongoing conflict and drought. Humanitarian aid efforts are underway to provide relief to those in need.
3. A new study published in a medical journal revealed that the Pfizer-BioNTech COVID-19 vaccine is highly effective in preventing hospitalizations and severe illness among children aged 12-15. The study cited a 97% efficacy rate in this age group.
4. The US Department of Labor announced that unemployment claims have reached a new pandemic low, with only 340,000 claims filed last week. This marks a significant improvement in the job market as businesses continue to reopen and hire new employees.
Read more at Nasdaq: Globus Medical (GMED) Q4 2024 Earnings Call Transcript